

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 January 2018 (25.01.2018)



(10) International Publication Number
WO 2018/015433 A3

(51) International Patent Classification:

G06F 19/00 (2018.01) A61K 39/00 (2006.01)
C12Q 1/68 (2018.01)

(21) International Application Number:

PCT/EP2017/068226

(22) International Filing Date:

19 July 2017 (19.07.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2016/067348

20 July 2016 (20.07.2016)

EP

(71) Applicant: BIONTECH RNA PHARMACEUTICALS

GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz
(DE).

(72) Inventors: TADMOR, Arbel D.; Am Anger 10, 55294 Bo-

denheim (DE). SAHIN, Ugur; Philipp-von-Zabern-Platz 1,
55116 Mainz (DE).

(74) Agent: SCHNAPPAUF, Georg; ZSP Patentanwälte PartG

mbB, Hansastrasse 32, 80686 München (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: SELECTING NEOEPITOPES AS DISEASE-SPECIFIC TARGETS FOR THERAPY WITH ENHANCED EFFICACY

(57) Abstract: The present invention relates to methods for determining whether neoepitopes that are only expressed in or on diseased cells are suitable disease-specific targets, such that the diseased cell is less likely to be able to escape immune surveillance, and use of the neoepitopes in providing an immune response against diseased cells expressing the neoepitopes.



WO 2018/015433 A3